Measles, Mumps and Rubella Vaccine Live (PRIORIX)
Measles, Mumps and Rubella Vaccine Live is an FDA-licensed reference biologic from GlaxoSmithKline Biologicals. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2022
Reference approved
Reference product
PRIORIX Measles, Mumps and Rubella Vaccine Live
GlaxoSmithKline Biologicals
- Approved
- Jun 03, 2022
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Measles, Mumps and Rubella Vaccine Live, in chronological order.
Reference approval
Approval date of the reference Measles, Mumps and Rubella Vaccine Live product.
4 yr 1 mo ago
Frequently asked questions
Are there biosimilars approved for Measles, Mumps and Rubella Vaccine Live (PRIORIX)?
No 351(k) biosimilars or interchangeable biosimilars referencing Measles, Mumps and Rubella Vaccine Live are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.